Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals

Executive Summary

Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.

Advertisement

Related Content

FDA Stretching Available Funds, Skeleton Workforce In Gov Shutdown Week Three
Shutdown Week Three: Sponsors With Upcoming User Fee Dates Should Start Sweating
OTC Switch For Naloxone Finding Interest Among Sponsors
OTC Switch For Naloxone Finding Interest Among Sponsors
Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue
Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel